Navigation Links
Pieris Initiates Phase I Clinical Trial for Lead Anticalin Compound
Date:6/15/2010

FREISING-WEIHENSTEPHAN, Germany, June 15, 2010 /PRNewswire/ -- Pieris AG announced today the initiation of a Phase I clinical trial in cancer patients for its lead program, PRS-050, an anti-VEGF Anticalin. The trial is an open-label, dose-escalating evaluation of the compound's safety and tolerability in patients with solid tumors. Conducted at three sites in Germany, the trial is underway and patients from the first cohort have been dosed.

"Meeting our goal of initiating this trial in the first half of 2010 demonstrates Pieris' commitment to establishing the safety and the therapeutic relevance of the Anticalin drug class," stated Stephen Yoder, CEO of Pieris. "Further, the high potency observed in preclinical studies, together with the small size and the lack of an antibody Fc domain, show promise of an attractive combined efficacy and safety profile for PRS-050."

The trial is designed to test PRS-050 in approximately 40 patients, who will receive the compound and then be monitored for safety and tolerability. The patients recruited for the trial are cancer patients with advanced, recurrent or metastatic solid tumors, refractory to standard therapy.

PRS-050 is an anti-VEGF (Vascular Endothelial Growth Factor) Anticalin discovered and developed internally at the company from Pieris' proprietary Anticalin libraries. PRS-050's mechanism of action is based on its ability to bind the VEGF ligand, thereby inhibiting tumor growth. VEGF's role in cancer angiogenesis, the mechanism by which cancer tumors increase blood vessel development to deliver key nutrients and oxygen is well established, both scientifically and clinically.

About Pieris


'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pieris Announces Positive Preclinical Data on c-Met Anticalin Drug Program
2. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
3. Pieris AG Enters into Anticalin Collaboration With Allergan, Inc.
4. Pieris Raises EUR 25 M (US$ 38 M) in Series B Financing Round
5. Pieris Validates the Use of Anticalins(R) as Ophthalmologic Biotherapeutics
6. Onyx Pharmaceuticals Initiates Phase 1 Study of Oral Proteasome Inhibitor in Advanced Solid Tumors
7. NewLink Initiates Pivotal Phase 3 Clinical Trial of HyperAcute(R)-Pancreas Immunotherapy for Resected Pancreatic Cancer
8. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-111 and Herceptin in Patients with Advanced Her2 Positive Breast Cancer
9. Fibrocell Science, Inc. Initiates Histology Study of azficel-T
10. Chimerix Initiates Phase 1 Study of CMX157
11. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015 Cutting-edge biotech ... food nutrition products reveal technological advancements are in ... such as hyperglycemia, obesity, insulin level issues and ... Biotech Companies in focus today are: RiceBran Technologies (NASDAQ: ... (NYSE: ANFI ), CEL-SCI Corporation (NYSE: ...
(Date:3/2/2015)... 02, 2015 Global Stem ... alliance with Shenzhen HANK Bioengineering Co., Ltd. and ... alliance will establish a stem cells training course ... in September 2015. , Shenzhen HANK is a ... award-winning scientist, microbiologist and virologist, to integrate research, ...
(Date:2/27/2015)... and SUMMERLAND, British Columbia , ... XON ), a leader in synthetic biology, ... acquire  Okanagan Specialty Fruits (OSF), the pioneering agricultural ... the world,s first non-browning apple. Through the acquisition, Intrexon ... that is more appetizing and convenient for consumers while ...
(Date:2/27/2015)... The fully automated supercritical fluidic chromatography-based ... analyze up to 48 samples utilizing automatic extraction ... targets by mass spectrometry. , The Nexera ... requirements of a wide range of applications, including ... search for disease biomarkers, additives in forming polymers, ...
Breaking Biology Technology:Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 2Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 3Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 4Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 5Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 6Clinical Studies & Research Substantiate Claims That Company's Targeted Healthy Nutritional Products Promote Healthy Lipids, Glucose & Insulin Levels 7Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Intrexon to Acquire Okanagan Specialty Fruits 2Intrexon to Acquire Okanagan Specialty Fruits 3Intrexon to Acquire Okanagan Specialty Fruits 4Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3
... SHORT HILLS, N.J., Jan. 23 Peter T. Wilderotter, ... Foundation, issued the following statement today in response to ... stem cell-based therapy:"This is an exciting first step for ... may improve due to advances in medical research. There ...
... Jan. 22 ScienceFirst is pleased to ... the Cedar Knolls office.(Photo: http://www.newscom.com/cgi-bin/prnh/20090122/NY61733-a ... Sudakin, PhD, has been named science manager. ... investigator at GlaxoSmithKline, where he co-lead the ...
... Hutchinson Cancer Research Center,s,stem-cell transplant program at the ... two transplant programs nationwide that consistently outperformed,the expected ... an independent report that assessed 122 transplant centers ... The Center for International Blood and Marrow Transplant ...
Cached Biology Technology:Christopher and Dana Reeve Foundation Response to FDA Clearance of Geron's Clinical Trial 2ScienceFirst Staff Expansion 2Transplant Program Tops in Expected One-Year Survival Rate 2
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/5/2015)... Carolina , 5. Februar 2015 /PRNewswire/ ... als spezialisiertes Logistikunternehmen und hat eine neue ... klinische Logistikfirma (Clinical Logistics Organization – CLO) ... neuen Kampagne lautet First , mit ... Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... January 28, 2015 New Market ... And Segment Forecasts To 2020 has Been Added to ... market is expected to reach USD 5.10 billion by ... Research, Inc. IR cameras help identify the site of ... to witness surging demand in medical imaging applications. They ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... expand and generate a lot of smoke visible on NASA ... blowing the smoke to the north-northeast and into Wyoming and ... Fire is located approximately 15 miles west of Fort Collins, ... homes have been lost, according to the U.S. Forest Service. ...
... teenagers and young women, but a new study reveals that age ... over, 3.5% report binge eating, nearly 8% report purging, and more ... the International Journal of Eating Disorders revealed that 62% ... their life. The researchers, led by Dr Cynthia Bulik, Director ...
... research shows that omega-3 fatty acid supplements can lower ... suggesting that regular use of these supplements could help ... of omega-3 supplementation decreased one protein in the blood ... of more than 10 percent, and led to a ...
Cached Biology News:Eating disorder behaviors and weight concerns are common in women over 50 2Omega-3 lowers inflammation in overweight older adults 2Omega-3 lowers inflammation in overweight older adults 3Omega-3 lowers inflammation in overweight older adults 4
This thermal printer, 120 V, provides a permanent record of the preprogrammed method and run data for the PROTEAN IEF cell. Includes cable and power adaptor....
... this kit to purify genomic DNA from plants in ... beating in a deep well plate using large zirconia ... a high velocity plate shaker (available through Mo Bio). ... silica membrane spin filter plate. The DNA is washed ...
... thermal cycler with 384-well reaction module is ... It is equipped with an interchangeable, 384-well ... algorithm temperature monitoring and control and ramp ... volumes. It includes the iCycler base with ...
... array systems, known as ChemiArrayTM Mouse ... compared with current methodologies. Besides the ... systems present a more accurate reflection ... only detect secreted cytokines, and no ...
Biology Products: